Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence
ReviewHumansOther animals
- Design
- Review
- Subjects
- Systematic review of human and animal studies
- Dose used in the study
- Varied
- Duration
- Not applicable
- What was measured
- Endocannabinoid and PEA levels and signalling in autism; supplementation studies
What the authors reported
Altered PEA and endocannabinoid levels and receptor expression are reported in autism. Limited research suggests supplementation reduced overall severity with better language and social behaviour.
Limits of this study
The supplementation evidence the authors call limited is, on this site, one add-on trial with risperidone (Khalaj 2018) and case reports. One author consults for GW Pharma outside this work.
Source
PubMed 33919499 · doi:10.3390/nu13041346
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.